Literature DB >> 33607149

Exploring the "Other" subfamily of HECT E3-ligases for therapeutic intervention.

Sunil Singh1, Joel Ng1, J Sivaraman2.   

Abstract

The HECT E3 ligase family regulates key cellular signaling pathways, with its 28 members divided into three subfamilies: NEDD4 subfamily (9 members), HERC subfamily (6 members) and "Other" subfamily (13 members). Here, we focus on the less-explored "Other" subfamily and discuss the recent findings pertaining to their biological roles. The N-terminal regions preceding the conserved HECT domains are significantly diverse in length and sequence composition, and are mostly unstructured, except for short regions that incorporate known substrate-binding domains. In some of the better-characterized "Other" members (e.g., HUWE1, AREL1 and UBE3C), structure analysis shows that the extended region (~ aa 50) adjacent to the HECT domain affects the stability and activity of the protein. The enzymatic activity is also influenced by interactions with different adaptor proteins and inter/intramolecular interactions. Primarily, the "Other" subfamily members assemble atypical ubiquitin linkages, with some cooperating with E3 ligases from the other subfamilies to form branched ubiquitin chains on substrates. Viruses and pathogenic bacteria target and hijack the activities of "Other" subfamily members to evade host immune responses and cause diseases. As such, these HECT E3 ligases have emerged as potential candidates for therapeutic drug development.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; E3 ubiquitin ligase; Posttranslational modification; Protein Degradation; Ubiquitination; “Other” subfamily HECT

Mesh:

Substances:

Year:  2021        PMID: 33607149     DOI: 10.1016/j.pharmthera.2021.107809

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  6 in total

1.  P38α MAPK is a gatekeeper of uterine progesterone responsiveness at peri-implantation via Ube3c-mediated PGR degradation.

Authors:  Yedong Tang; Jingtao Qiu; Zhenzhou Tang; Gaizhen Li; Mengqing Gu; Yang Wang; Haili Bao; Wenbo Deng; Zhongxian Lu; Kinya Otsu; Zhengchao Wang; Haibin Wang; Shuangbo Kong
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

2.  HUWE1 Causes an Immune Imbalance in Immune Thrombocytopenic Purpura by Reducing the Number and Function of Treg Cells Through the Ubiquitination Degradation of Ets-1.

Authors:  Jianqin Li; Yalin Xia; Xiaoru Fan; Xiaofang Wu; Feiyun Yang; Shaoyan Hu; Zhaoyue Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-25

Review 3.  Modulating the Ubiquitin-Proteasome System: A Therapeutic Strategy for Autoimmune Diseases.

Authors:  Dhananjay Yadav; Ji Yeon Lee; Nidhi Puranik; Pallavi S Chauhan; Vishal Chavda; Jun-O Jin; Peter C W Lee
Journal:  Cells       Date:  2022-03-24       Impact factor: 6.600

4.  Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm.

Authors:  Weijing Cai; Ranjala Ratnayake; Mengxiong Wang; Qi-Yin Chen; Kevin P Raisch; Long H Dang; Brian K Law; Hendrik Luesch
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-09-08

Review 5.  Research progress of Nedd4L in cardiovascular diseases.

Authors:  Mohan Li; Guozhe Sun; Pengbo Wang; Wenbin Wang; Kexin Cao; Chunyu Song; Yingxian Sun; Ying Zhang; Naijin Zhang
Journal:  Cell Death Discov       Date:  2022-04-16

Review 6.  The emerging role of WWP1 in cancer development and progression.

Authors:  Xiaoli Hu; Jiangtao Yu; Zixia Lin; Renqian Feng; Zhi-Wei Wang; Gang Chen
Journal:  Cell Death Discov       Date:  2021-06-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.